PIK3CA mutations often result in hyperactivation of the PI3K/AKT/mTOR pathway, which is associated with oncogenesis, tumor development, and resistance to endocrine therapy in HR‐positive, HER2‐negative ABC.21, 22, 23, 24, 25. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.